REG - Proteome Sciences - AGM Statement

Proteome SciencesAnnouncement

30/05/2018 13:40

RNS Number : 7124P
Proteome Sciences PLC
30 May 2018
 


30 May 2018
 
 
 
 
 
Proteome Sciences plc
("Proteome Sciences" or the "Company")
 
AGM Statement and Result of AGM
 
 
At the AGM held earlier today the CEO, Jeremy Haigh, made a brief statement:
 
 "As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT® strengthens.   Trading is broadly in line with expectations despite a characteristically slower first quarter, and the services business continues to demonstrate significant growth.   While the Company remains cash constrained, we have had discussions with a number of our larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business."
 
All resolutions at the AGM were duly passed.
 
For further information:
 




Proteome Sciences plc




Dr Jeremy Haigh, Chief Executive Officer


Tel: +44 (0)20 7043 2116




Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer


















finnCap Limited (Nominated Adviser & Broker) 




Geoff Nash/Hannah Boros (Corporate Finance)
Abigail Wayne (Broking)


Tel: +44 (0)20 7220 0500
 
 




 
About Proteome Sciences plc. (www.proteomics.com)
 
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
 
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMAMMTTMBJJBIP